Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?

Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Viviana De Martino, Michela Rossi, Giulia Battafarano, Jessica Pepe, Salvatore Minisola, Andrea Del Fattore
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	osteosarcoma extracellular vesicles therapy Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/68cedf16b09346ff86a5c64e9486d71e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68cedf16b09346ff86a5c64e9486d71e
record_format	dspace
spelling	oai:doaj.org-article:68cedf16b09346ff86a5c64e9486d71e2021-11-25T17:58:04ZExtracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?10.3390/ijms2222125861422-00671661-6596https://doaj.org/article/68cedf16b09346ff86a5c64e9486d71e2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12586https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutics. However, the drug resistance and the side effects associated with the chemotherapy require the identification of new therapeutic approaches. The understanding of the complex biological scenario of the osteosarcoma will open the way for the identification of new targets for its treatment. Recently, a great interest of scientific community is for extracellular vesicles (EVs), that are released in the tumor microenvironment and are important regulators of tumor proliferation and the metastatic process. At the same time, circulating extracellular vesicles can be exploited as diagnostic and prognostic biomarkers, and they can be loaded with drugs as a new therapeutic approach for osteosarcoma patients. Thus, the characterization of OS-related EVs could represent a way to convert these vesicles from antagonists for human health into therapeutic and/or diagnostic agents.Viviana De MartinoMichela RossiGiulia BattafaranoJessica PepeSalvatore MinisolaAndrea Del FattoreMDPI AGarticleosteosarcomaextracellular vesiclestherapyBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12586, p 12586 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteosarcoma extracellular vesicles therapy Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	osteosarcoma extracellular vesicles therapy Biology (General) QH301-705.5 Chemistry QD1-999 Viviana De Martino Michela Rossi Giulia Battafarano Jessica Pepe Salvatore Minisola Andrea Del Fattore Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
description	Osteosarcoma (OS) is a skeletal tumor affecting mainly children and adolescents. The presence of distance metastasis is frequent and it is localized preferentially to the lung, representing the main reason for death among patients. The therapeutic approaches are based on surgery and chemotherapeutics. However, the drug resistance and the side effects associated with the chemotherapy require the identification of new therapeutic approaches. The understanding of the complex biological scenario of the osteosarcoma will open the way for the identification of new targets for its treatment. Recently, a great interest of scientific community is for extracellular vesicles (EVs), that are released in the tumor microenvironment and are important regulators of tumor proliferation and the metastatic process. At the same time, circulating extracellular vesicles can be exploited as diagnostic and prognostic biomarkers, and they can be loaded with drugs as a new therapeutic approach for osteosarcoma patients. Thus, the characterization of OS-related EVs could represent a way to convert these vesicles from antagonists for human health into therapeutic and/or diagnostic agents.
format	article
author	Viviana De Martino Michela Rossi Giulia Battafarano Jessica Pepe Salvatore Minisola Andrea Del Fattore
author_facet	Viviana De Martino Michela Rossi Giulia Battafarano Jessica Pepe Salvatore Minisola Andrea Del Fattore
author_sort	Viviana De Martino
title	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_short	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_full	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_fullStr	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_full_unstemmed	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?
title_sort	extracellular vesicles in osteosarcoma: antagonists or therapeutic agents?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/68cedf16b09346ff86a5c64e9486d71e
work_keys_str_mv	AT vivianademartino extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents AT michelarossi extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents AT giuliabattafarano extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents AT jessicapepe extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents AT salvatoreminisola extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents AT andreadelfattore extracellularvesiclesinosteosarcomaantagonistsortherapeuticagents
_version_	1718411807400394752

Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?

Ejemplares similares